There is growing evidence of the importance of
protease-activated receptor 4 (PAR4), one of
thrombin receptors, as a therapeutic target in thrombotic
cardiovascular diseases. In the present study, we utilized
ligand-based virtual screening, bioassay, and structure-activity relationship study to discover PAR4 antagonists with new chemical scaffolds from natural origin, and examined their application as
antiplatelet agents. By using these approaches, we have identified a
flavonoid, 7, 4'-dimethoxy-3-hydroxyflavone, that exhibits anti-PAR4 activity. 7, 4'-Dimethoxy-3-hydroxyflavone inhibited PAR4-mediated human platelet aggregation, GPIIb/IIIa activation, and
P-selectin secretion. Also, it inhibited PAR4 downstream signaling pathways, including Ca2+/
protein kinase C, Akt, and MAP
kinases ERK and p38, in human platelets, and suppressed PAR4-mediated β-
arrestin recruitment in CHO-K1 cells exogenously expressed human PAR4. In a microfluidic system, 7, 4'-dimethoxy-3-hydroxyflavone reduced
thrombus formation on
collagen-coated chambers at an arterial shear rate in recalcified whole blood. Furthermore, mice treated with 7, 4'-dimethoxy-3-hydroxyflavone were significantly protected from FeCl3-induced carotid
arterial occlusions, without significantly affecting tail bleeding time. In conclusion, 7, 4'-dimethoxy-3-hydroxyflavone represents a new class of nature-based PAR4 antagonist, it shows effective in vivo antithrombotic properties with less
bleeding tendency, and could be a potential candidate for developing new
antiplatelet agents.